Analyst Price Target is $18.25
▲ +174.85% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Zura Bio in the last 3 months. The average price target is $18.25, with a high forecast of $22.00 and a low forecast of $14.00. The average price target represents a 174.85% upside from the last price of $6.64.
Current Consensus is
The current consensus among 4 contributing investment analysts is to buy stock in Zura Bio. This Buy consensus rating has held steady for over two years.
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.